Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Oracle’s AI Ambition Faces a Costly Reality Check

Andreas Sommer by Andreas Sommer
December 13, 2025
in AI & Quantum Computing, Analysis, Earnings, Tech & Software, Value & Growth
0
Oracle Stock
0
SHARES
17
VIEWS
Share on FacebookShare on Twitter

Investor sentiment toward Oracle has soured dramatically, shifting from optimism over its artificial intelligence push to deep concern over its financial implications. The software giant’s aggressive bid for market leadership in AI is now being overshadowed by ballooning expenditure forecasts and conflicting reports about its pivotal partnership with OpenAI. While the company’s order backlog reaches unprecedented heights, a pressing question emerges on Wall Street: can Oracle manage the staggering costs of its growth strategy without compromising its financial health?

The Staggering $50 Billion Bet

The core driver behind the recent sell-off lies in the latest quarterly figures, which laid bare the immense price tag of Oracle’s expansion. To meet soaring demand for AI infrastructure, the company is committing to massive capital investment. Management sharply raised its full-year capital expenditure (CapEx) forecast, lifting it from $35 billion to a total of $50 billion.

This aggressive spending plan is putting significant pressure on liquidity. The revised numbers prompted swift reactions from major financial institutions. Analysts at Goldman Sachs drastically cut their price target for Oracle shares from $320 to $220. Similarly, Citi and UBS revised their expectations downward. The primary worry among experts is the growing disconnect between future profit potential and the immediate, substantial cash outlays required.

A Snapshot of the Financial Strain:

Should investors sell immediately? Or is it worth buying Oracle?

  • Capital Expenditure Forecast: Increased to $50 billion, representing an additional $15 billion in planned spending.
  • Free Cash Flow: Turned negative, reported at -$10 billion for the first half of the year.
  • Remaining Performance Obligation (RPO): Hit a record $523 billion, a year-over-year increase of 438%.
  • Total Debt: Has risen to over $105 billion.

Confusion Over the OpenAI Partnership

Adding to investor anxiety, a Bloomberg report late last week introduced fresh uncertainty. It suggested that construction of new data centers for key AI client OpenAI could face delays stretching into 2028, citing shortages of materials and personnel. Oracle was quick to dispute this characterization, asserting that all contractual milestones were on track. However, the damage to market confidence was done. Given that the OpenAI alliance is central to Oracle’s current growth narrative, any hint of disruption triggers heightened sensitivity among investors.

Technical Chart Damage

The combination of exploding costs and partnership concerns has inflicted clear technical damage on Oracle’s stock chart. The equity shed approximately 13.5% over the week, breaking below the critical 200-day moving average at 187.08 euros—a classic warning signal for institutional investors. The share price now trades around 161.56 euros, perilously close to its lowest levels in the past twelve months.

Oracle finds itself in a precarious balancing act. The long-term growth story, supported by a colossal order backlog, remains theoretically intact. Yet, the short-term financial burden of funding that growth is substantial. In the coming months, management must demonstrate that its aggressive spending can be converted into tangible cash flow before the mounting debt load exerts further pressure on the company’s valuation.

Ad

Oracle Stock: Buy or Sell?! New Oracle Analysis from February 7 delivers the answer:

The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Oracle: Buy or sell? Read more here...

Tags: Oracle
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
Procter & Gamble Stock

Procter & Gamble Shares Find Relief as Tariff Forecasts Ease

Nvidia Stock

Washington Divided Over Trump's Nvidia Chip Export Decision

Micron Stock

Micron Shares Face Critical Test Amid Diverging Market Signals

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com